Clinigen has signed an exclusive agreement with Lukare Medical to manage the supply and distribution of Elliotts B Solution.
Under the terms of this supply and distribution agreement with Lukare, Clinigen will provide physicians and pharmacists with access to Elliotts B Solution on an unlicensed, on-demand basis for patients around the world, excluding the US and Canada.
Marketing authorisation is granted in the United States, but Elliotts B Solution is currently unavailable to meet patient needs elsewhere in the world.
Elliotts B Solution (buffered intrathecal electrolyte/dextrose injection) is a diluent for methotrexate sodium, a chemotherapeutic drug and immune system suppressant, and cytarabine, a chemotherapeutic drug. These products require intrathecal administration (into the cerebrospinal fluid) for the prevention or treatment of meningeal leukaemia or lymphocytic lymphoma.
Edwin Hernandez, CEO, Lukare Medical, said, “This relationship will greatly enhance our ability to make Elliotts B Solution available to other regions of the world. We are confident many patients and researchers will benefit from the opportunity to use Elliotts B Solution.”